166 related articles for article (PubMed ID: 109513)
1. Characterization of the spontaneous murine B cell leukemia (BCL1). III. Evidence for monoclonality by using an anti-idiotype antibody.
Vitetta ES; Yuan D; Krolick K; Isakson P; Knapp M; Slavin S; Strober S
J Immunol; 1979 May; 122(5):1649-54. PubMed ID: 109513
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of a B cell leukemia: evidence implicating an anti-idiotype immune response for protective tumor immunity.
Ciavarra RP; Vitetta ES; Forman J
J Immunol; 1986 Aug; 137(4):1371-5. PubMed ID: 2426362
[TBL] [Abstract][Full Text] [Related]
3. Murine B cell leukemia (BCL1): organ distribution and kinetics of growth as determined by fluorescence analysis with an anti-idiotypic antibody.
Krolick KA; Isakson PC; Uhr JW; Vitetta ES
J Immunol; 1979 Nov; 123(5):1928-35. PubMed ID: 385772
[TBL] [Abstract][Full Text] [Related]
4. Influence of IgH V-region genes on the growth kinetics of a murine B cell leukemia (BCL1).
Ciavarra R; Forman J
J Immunol; 1981 Jan; 126(1):54-8. PubMed ID: 6778917
[TBL] [Abstract][Full Text] [Related]
5. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.
George AJ; Tutt AL; Stevenson FK
J Immunol; 1987 Jan; 138(2):628-34. PubMed ID: 3491853
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of a murine B cell tumor with antibodies and F(ab')2 fragments against idiotypic determinants of its cell surface IgM.
Perek Y; Hurwitz E; Burowski D; Haimovich J
J Immunol; 1983 Sep; 131(3):1600-3. PubMed ID: 6604103
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a spontaneous murine B cell leukemia (BCL1). I. Cell surface expression of IgM, IgD, Ia, and FcR.
Knapp MR; Jones PP; Black SJ; Vitetta ES; Slavin S; Strober S
J Immunol; 1979 Sep; 123(3):992-9. PubMed ID: 313960
[TBL] [Abstract][Full Text] [Related]
8. Molecules recognized by anti-idiotypic monoclonal antibodies to the B cell lymphoma, BCL1.
Tamura GS; McGrath MS; Weissman IL
J Mol Cell Immunol; 1987; 3(4):243-53. PubMed ID: 3509925
[TBL] [Abstract][Full Text] [Related]
9. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation.
Stevenson FK; Gordon J
J Immunol; 1983 Feb; 130(2):970-3. PubMed ID: 6600259
[TBL] [Abstract][Full Text] [Related]
10. Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells.
King CA; Wills MR; Hamblin TJ; Stevenson FK
Cell Immunol; 1993 Apr; 147(2):411-24. PubMed ID: 8095858
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a spontaneous murine B cell leukemia (BCL1). II. Tumor cell proliferation and IgM secretion after stimulation by LPS.
Knapp MR; Severinson-Gronowicz E; Schröder J; Strober S
J Immunol; 1979 Sep; 123(3):1000-6. PubMed ID: 381513
[TBL] [Abstract][Full Text] [Related]
12. Loss of surface-bound antibody accompanying the anti-complementary modulation of leukemic B cell immunoglobulin: contrasting effects of antibodies directed against idiotypic and constant regions.
Gordon J; Anderson VA; Stevenson GT
J Immunol; 1982 Jun; 128(6):2863-9. PubMed ID: 6804570
[TBL] [Abstract][Full Text] [Related]
13. Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma.
Weiner GJ; Kaminski MS
J Immunol; 1989 Jan; 142(1):343-51. PubMed ID: 2783325
[TBL] [Abstract][Full Text] [Related]
14. Circulating monoclonal IgM proteins in B cell chronic lymphocytic leukemia: their identification, characterization and relationship to membrane IgM.
Qian GX; Fu SM; Solanki DL; Rai KR
J Immunol; 1984 Dec; 133(6):3396-400. PubMed ID: 6333459
[TBL] [Abstract][Full Text] [Related]
15. Antigen-induced murine B cell lymphomas. II. Exploitation of the surface idiotype as tumor specific antigen.
Haughton G; Lanier LL; Babcock GF; Lynes MA
J Immunol; 1978 Dec; 121(6):2358-62. PubMed ID: 82581
[TBL] [Abstract][Full Text] [Related]
16. Receptor mediated leukemogenesis: murine leukemia virus interacts with BCL1 lymphoma cell surface IgM.
McGrath MS; Tamura G; Weissman IL
J Mol Cell Immunol; 1987; 3(4):227-42. PubMed ID: 2855408
[TBL] [Abstract][Full Text] [Related]
17. Some effects on leukaemic B lymphocytes of antibodies to defined regions of their surface immunoglobulin.
Stevenson FK; Elliott EV; Stevenson GT
Immunology; 1977 Apr; 32(4):549-57. PubMed ID: 415966
[TBL] [Abstract][Full Text] [Related]
18. Idiotypic analysis of a B cell clone with anti-intermediate filament specificity in a patient with Sjögren's syndrome: involvement of five subpopulations producing different immunoglobulin isotypes.
Landay A; Kubagawa H; Cooper MD
J Immunol; 1986 Jul; 137(1):129-36. PubMed ID: 3086445
[TBL] [Abstract][Full Text] [Related]
19. Idiotypic vaccination as a treatment for a B cell lymphoma.
George AJ; Folkard SG; Hamblin TJ; Stevenson FK
J Immunol; 1988 Sep; 141(6):2168-74. PubMed ID: 3049800
[TBL] [Abstract][Full Text] [Related]
20. IgM expressed by leukemic CD5(+) B cells binds mouse immunoglobulin light chain.
Weston KM; Tangye SG; Dunn RD; Smith A; Morris MB; Raison RL
J Mol Recognit; 2001; 14(4):245-53. PubMed ID: 11500971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
